Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

NCT03232424 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT03232424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03232424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Lead sponsor
Hackensack Meridian Health
Phase
Phase 1
Overall status
Completed
Start date
July 26, 2017
Completion date
December 7, 2022
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, adult